Drug
Cohort A Dxc016 Dose Escalation
Cohort A Dxc016 Dose Escalation: highest development phase Phase 1, developed by Hangzhou DAC Biotechnology Co., Ltd.. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Hangzhou DAC Biotechnology Co., Ltd.
Trials
| Drug | Phase | Indication |
|---|---|---|
| Cohort A: DXC016 dose escalation NCT07932899 | Phase 1 | Advanced Solid Tumors |
Latest
No recent events.
Follow Cohort A Dxc016 Dose Escalation on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.